Ibrexafungerp (formerly SCY-078): An
Innovative Antifungal

Ibrexafungerp Overview

Ibrexafungerp (formerly SCY-078) is the first representative of a novel class of structurally-distinct glucan synthase inhibitors, triterpenoids. It has shown activity against Aspergillus and Candida, including against multidrug-resistant (MDR) species Candida auris as well as Pneumocystis. Ibrexafungerp combines the well-established activity of glucan synthase inhibitors with the flexibility of oral and IV formulations, offering a broad use across different settings (in-patient and out-patient).

We believe that ibrexafungerp has the potential to be an essential therapy in the treatment of multiple serious fungal infections, including vulvovaginal candidiasis (VVC), invasive candidiasis, invasive aspergillosis and refractory invasive fungal infections.

Initial Target Indications

Vulvovaginal Candidiasis

Vulvovaginal Candidiasis

View Indication
Invasive Candidiasis

Invasive Candidiasis

View Indication
Invasive Aspergillosis

Invasive Aspergillosis

View Indication
Refractory Invasive Fungal Infections

Refractory Invasive Fungal Infections

View Indication

Development Status

These timelines are subject to change due to regulatory, clinical and other considerations.

Indication Pre-Clinical Phase 1 Phase 2 Phase 3 NDA Filing
Acute Vulvovaginal Candidiasis
Pre-Clinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
NDA Filing Phase not started
Recurrent Vulvovaginal Candidiasis
Pre-Clinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
NDA Filing Phase not started
Invasive Candidiasis
Pre-Clinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
NDA Filing Phase not started
Invasive Aspergillosis Combo
Pre-Clinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
NDA Filing Phase not started
Refractory Invasive Fungal Infections
Pre-Clinical Phase complete
Phase 1 Phase complete
Phase 2 Phase complete
Phase 3 Phase in progress
NDA Filing Phase not started

Upcoming Milestones

Milestone Timing
Initiate Phase 2 Combo Study in Invasive Aspergillosis Q3 2018
Initiate VVC Phase 3 Program Q4 2018
FURI & CARES Studies Preliminary Data Review Q4 2018